Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Accenture
Mallinckrodt
AstraZeneca
US Army
Fish and Richardson
US Department of Justice
Medtronic

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021532

« Back to Dashboard

NDA 021532 describes BENICAR HCT, which is a drug marketed by Daiichi Sankyo and is included in one NDA. It is available from six suppliers. Additional details are available on the BENICAR HCT profile page.

The generic ingredient in BENICAR HCT is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.
Summary for 021532
Tradename:BENICAR HCT
Applicant:Daiichi Sankyo
Ingredient:hydrochlorothiazide; olmesartan medoxomil
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021532
Ingredient-typeThiazides
Mechanism of ActionAngiotensin 2 Receptor Antagonists
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 021532
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532 NDA A-S Medication Solutions 50090-1083 N 50090-1083-0
BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532 NDA Cardinal Health 55154-6125 N 55154-6125-2

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;20MG
Approval Date:Jun 5, 2003TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;40MG
Approval Date:Jun 5, 2003TE:ABRLD:Yes

Profile for product number 005

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;40MG
Approval Date:Jun 5, 2003TE:ABRLD:Yes

Expired US Patents for NDA 021532

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-005 Jun 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-002 Jun 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-003 Jun 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Merck
Covington
Johnson and Johnson
McKesson
Fuji
Federal Trade Commission
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.